Relaxin/insulin-like family peptide receptor 4
Relaxin/insulin-like family peptide receptor 4 (RXFP4) is a G protein-coupled receptor (GPCR) that is part of the relaxin family of receptors. It is primarily involved in the regulation of various physiological processes through its interaction with specific peptide ligands.
Structure[edit | edit source]
RXFP4 is a member of the class A GPCRs, characterized by seven transmembrane domains. The receptor is encoded by the RXFP4 gene located on chromosome 1. The protein structure includes an extracellular N-terminus, seven transmembrane helices, and an intracellular C-terminus.
Function[edit | edit source]
RXFP4 is known to bind to relaxin family peptides, particularly insulin-like peptide 5 (INSL5). Upon ligand binding, RXFP4 activates intracellular signaling pathways, primarily through the Gαi protein, leading to a decrease in cyclic adenosine monophosphate (cAMP) levels.
Physiological Role[edit | edit source]
RXFP4 is expressed in various tissues, including the gastrointestinal tract, where it plays a role in regulating appetite and energy homeostasis. It is also involved in modulating glucose metabolism and insulin sensitivity.
Clinical Significance[edit | edit source]
Alterations in RXFP4 expression or function have been implicated in metabolic disorders such as obesity and type 2 diabetes mellitus. Understanding the role of RXFP4 in these conditions could lead to the development of novel therapeutic strategies.
Ligands[edit | edit source]
The primary endogenous ligand for RXFP4 is INSL5. Research is ongoing to identify other potential ligands and to develop synthetic agonists or antagonists that could modulate RXFP4 activity for therapeutic purposes.
Research Directions[edit | edit source]
Current research is focused on elucidating the detailed signaling mechanisms of RXFP4 and its role in metabolic regulation. Studies are also exploring the potential of RXFP4 as a target for drug development in the treatment of metabolic diseases.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
